MaxCyte (MXCT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
MaxCyte reported a 2% increase in total revenue for the third quarter of 2024, with core business revenue rising by 23% compared to the previous year. The company signed six new Strategic Platform License clients, bringing the total to 29, and is considering focusing its trading solely on the NASDAQ exchange to improve liquidity. MaxCyte expects to end the year with approximately $185 million in cash and investments.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
